Abstract
Recombinant Oka varicella-hepatitis B virus (HBV) vaccine was constructed by inserting the HBV surface antigen (HBsAg) gene coding partial PreS2 and whole S regions into the viral thymidine kinase gene. HBsAg was expressed in the cytoplasm of infected cells. Intracellular HBsAg (26K and 30K) was N- and O-glycosylated, sialylated, and secreted into the supernatant as 30K and 35K HBsAg particles. Recombinant virus induced antibody response to both varicella-zoster virus and HBsAg in guinea pigs and the level of antibody titers to HBsAg was comparable in guinea pigs immunized with a live varicella-HBV vaccine or commercial HBs subunit vaccine. Altogether, this recombinant virus may be a good candidate for the live varicella-HBV vaccine.
| Original language | English |
|---|---|
| Pages (from-to) | 241-247 |
| Number of pages | 7 |
| Journal | Nihon rinsho. Japanese journal of clinical medicine |
| Volume | 51 |
| Issue number | 1 |
| State | Published - 1993/01 |
ASJC Scopus subject areas
- General Medicine
